JCM
BIIB icon

JS Capital Management’s Biogen BIIB Stock Holding History

JS Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-31,000
Closed -$9.7M – 9
2016
Q3 		$9.7M Sell
31,000
-12,900
-29% -$3.82M 3.73% 6
2016
Q2 		$10.6M Buy
43,900
+9,400
+27% +$2.48M 2.05% 6
2016
Q1 		$8.98M Buy
34,500
+22,500
+188% +$5.94M 1.61% 8
2015
Q4 		$3.68M Buy
+12,000
New +$3.45M 0.87% 19

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JS Capital Management's BIIB Position: Q4 2016 in Review

JS Capital Management sold out of Biogen (BIIB) in Q4 2016, closing a stake of 31,000 shares — an estimated $9.7M sold.

JS Capital Management first reported a position in BIIB in Q4 2015 and held it in 4 quarters. The position peaked at $10.6M in Q2 2016. 1,025 funds tracked by Wall St. Rank hold BIIB as of Q4 2016.

  • JS Capital Management reported no remaining Biogen position as of Q4 2016 after selling out during the quarter.
  • JS Capital Management sold 31,000 Biogen shares in Q4 2016, an estimated $9.7M.
  • JS Capital Management first reported a position in Biogen in Q4 2015 and held it in 4 quarters.
  • JS Capital Management's Biogen position peaked at $10.6M in Q2 2016.
  • 1,025 funds tracked by Wall St. Rank held Biogen as of Q4 2016.

Based on JS Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.